GlassScriptPhysician profile
Victor Pina
NPI 1164403846
$7,366.89
in general payments reported to CMS, 2019-2025
34 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,214 · 2020: $807 · 2021: $1,374 · 2022: $1,223 · 2023: $822 · 2024: $755 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,665 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,664.86 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,456.31 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,297.73 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $848.12 | 2020-2025 | Ocaliva |
| Janssen Biotech, INC. | $548.94 | 2020-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $528.69 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $407.23 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $366.57 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $275.71 | 2021-2024 | Eohilia, Entyvio |
| Phathom Pharmaceuticals, INC. | $238.10 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $170.43 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $165.61 | 2020-2021 | |
| Napo Pharmaceuticals INC | $125.00 | 2019 | |
| Braintree Laboratories, INC. | $107.17 | 2020-2025 | Sutab |
| Vivus LLC | $105.31 | 2021-2025 | Pancreaze, Qsymia |
| Lilly USA, LLC | $103.30 | 2023-2025 | Omvoh |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $94.41 | 2021-2025 | Gimoti |
| Ironwood Pharmaceuticals, INC | $80.58 | 2019-2023 | Linzess |
| Madrigal Pharmaceuticals | $79.07 | 2025 | Rezdiffra |
| Celgene Corporation | $49.49 | 2021 | |
| Daiichi Sankyo INC. | $37.40 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $36.08 | 2019 | |
| Pfizer INC. | $33.54 | 2025 | |
| Alnylam Pharmaceuticals INC. | $29.33 | 2022 | |
| Alfasigma USA, INC. | $28.47 | 2021-2022 | |
| Covidien LP | $24.42 | 2019 | |
| Novo Nordisk INC | $22.35 | 2025 | Wegovy |
| Dova Pharmaceuticals | $18.25 | 2019 | |
| Qol Medical, LLC | $17.21 | 2019 | |
| Romark Laboratories, Lc | $16.80 | 2019 | |
| Medtronic, INC. | $16.71 | 2022 | |
| Merck Sharp & Dohme LLC | $15.78 | 2022 | |
| Allergan, INC. | $15.51 | 2020 | |
| Organon LLC | $7.27 | 2025 | Hadlima |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Pina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.